with European approval expected later this year. Neuroscience total revenues were nearly $2.2 billion, up 15.2% on an operational basis. This robust performance is driven by continued double-digit growth of Vraylar with global sales of $774 million, Ubrelvy with total revenue of $231 million, and Qulipta with global sales of $150 million. Each of these leading assets continue to gain share and remain competitively well-positioned.